Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

151.19 +2.51 (+1.69%)
Streaming Delayed Price Updated: 3:45 PM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
News headline image
How Is The Market Feeling About Novartis? ↗
 
Via Benzinga
News headline image
2 Dividend Stocks to Buy and Hold ↗
These stocks look like they can weather almost any storm. 
Via The Motley Fool
Topics Artificial Intelligence Cannabis Government
News headline image
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Emerges as a Top Pick for Value Investors with Strong Fundamentals and Attractive Valuation ↗
Novartis AG-SPONSORED ADR (NVS) is a top pick for value investors, offering solid fundamentals, strong profitability, and a 3.76% dividend yield, all at an attractive valuation. 
Via Chartmill
News headline image
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate ↗
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease. 
Via Benzinga
News headline image
P/E Ratio Insights for Novartis ↗
 
Via Benzinga
Novartis Rides Bullish Retail Mood, Roche Faces Gloom Amid Swiss-US Trade Concerns ↗
Via Stocktwits
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium ↗
Via Stocktwits
News headline image
Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder ↗
Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial. 
Via Benzinga
News headline image
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point ↗
Truist, however, kept a ‘Buy’ rating on the shares. 
Via Stocktwits
News headline image
Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well ↗
Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease. 
Via Stocktwits
News headline image
Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva ↗
Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings. 
Via Benzinga
News headline image
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% ↗
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat. 
Via Benzinga
News headline image
2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever ↗
These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world. 
Via The Motley Fool
Topics ETFs
News headline image
PTCT Earnings Beat but Sales Drop 4% ↗
Via The Motley Fool
Topics Earnings
News headline image
Monte Rosa (GLUE) Q2 Revenue Jumps 394% ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Schrödinger (SDGR) Q2 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful ↗
Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. 
Via Stocktwits
Topics Earnings
News headline image
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal ↗
The company is focused on treatments for forms of muscular dystrophy. 
Via Investor's Business Daily
News headline image
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗
Via Stocktwits
Topics Government
News headline image
Hazelden Betty Ford Foundation Appoints Four New Members to Its Board of Trustees
Center City, Minnesota--(Newsfile Corp. - July 31, 2025) - Hazelden Betty Ford Foundation, the nation's leading nonprofit system of addiction... 
Via Newsfile
News headline image
15 regions chosen for groundbreaking effort to reduce cardiovascular disease
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs ↗
US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon. 
Via Benzinga
Topics Economy Government World Trade
News headline image
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients. 
Via Benzinga
News headline image
U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports
The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Top Dividend Stock with Strong Profitability and Financial Stability ↗
NOVARTIS AG (NVS) is a top dividend stock with a 3.76% yield, strong profitability, and financial stability, making it ideal for income-focused investors. 
Via Chartmill
News headline image
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies. ↗
Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues. 
Via Investor's Business Daily
Topics Death Workforce
News headline image
Screening for cardiovascular disease marker in community health centers may reduce risk
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
News headline image
Highest Ever for This International Stock ETF -- But Analysts Say It Has Room to Run ↗
Via The Motley Fool
Topics ETFs World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.